BioCentury
ARTICLE | Company News

Bionure Farma, Spiral Therapeutics deal

March 31, 2017 7:33 PM UTC

Bionure granted Spiral an option to acquire exclusive, worldwide rights to Bionure’s preclinical serum/glucocorticoid regulated kinase 2 (SGK2) agonists BN201 and BN119 to treat otolaryngology indications. Spiral plans to exercise the option by 3Q17. If exercised, Bionure will be eligible to receive up to $4.9 million in milestones, plus royalties...